Clinical Trial Search Results
A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks.
You, or you and the individual you care for, are being asked to take part in a research study because you have seizures associated with developmental and epileptic encephalopathy (DEE) and you have completed study LP352-201. L ...
A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately to Severely Active Crohn’s Disease with an Inadequate Response to Conventional Therapy
The purpose of this study is to see whether ozanimod (RPC1063, also referred to as the ‘study drug’ or ‘study treatment’) is safe and effective for the possible treatment of Crohn’s Disease (CD) in a pediatric population. To do ...
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
This study looks at how well a drug called selumetinib works when given to children and young adults with LGG. The study doctors want to see if selumetinib works as well as CV for getting rid of or shrinking LGGs and stopping t ...
A Phase 3 Randomized Study of Selumetinib (IND# 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The overall goals of this study are to see if selumetinib works just as well as the standard treatment of carboplatin/vincristine (CV) for subjects with NF1-associated LGG, and to see if selumetinib is better than CV in improvi ...
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
The overall goal of this study is to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better. This study will compare standard chemotherap ...
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Low Risk Subjects (Age <50 Years): The overall goal is to see if monitoring subjects with low risk germ cell tumors after their tumor is removed is as effective as following surgery with chemotherapy and/or more surgery. Sta ...
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
This study is being done to see how safe and effective four doses of the experimental drug oregovomab is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen paclitaxel and carbo ...
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis
This study is being done to help answer the following research questions: (a) How mirikizumab, an investigational drug, could help people with ulcerative colitis over time; (b) How safe long-term use of mirikizumab is; and (c) ...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.
The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: How safe mirikizumab is and whether you might have any side effects when you t ...